Clinical trials: Androgens
Prostate Cancer
Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
The objective of this study was to compare the efficacy and safety of the combination therapy with enzalutamide + androgen deprivation therapy (ADT) and the combination therapy with flutamide + ADT in patients with castration…
- Trial name
- NCT02918968
- Testing
- Enzalutamide, Flutamide, Androgen deprivation therapy
- Where
- 47 sites in Japan
- Volunteers
- 206 people
- Sponsor
- Astellas Pharma Inc
Bone Loss, Prostate Cancer
Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer
The primary objective of this study is to determine whether zoledronic acid (Zometa) given once annually increases bone mineral density in men receiving hormone therapy for prostate cancer.
- Trial name
- NCT00181584
- Testing
- Zoledronic acid
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Spinal Cord Injury, Spinal Cord Injuries
Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
This pilot study will determine the feasibility of implementing a combinatory rehabilitation strategy involving testosterone replacement therapy (TRT) with locomotor training (LT; walking on a treadmill with assistance and…
- Conditions
- Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System, Wounds and Injury
- Trial name
- NCT04460872
- Testing
- Testosterone Enanthate, Locomotor Training
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- North Florida Foundation for Research and Education
Prostate Adenocarcinoma, Prostate Cancer
Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
The goal of this research study is to determine whether hormonal therapies used early in the course of prostate cancer could increase the amount of Prostate-Specific Membrane Antigen (PSMA) as detected by PET/CT scans for…
- Conditions
- Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Trial name
- NCT05683964
- Testing
- Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi], Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Beth Israel Deaconess Medical Center
Prostate Cancer
Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00096304
- Testing
- docetaxel, epirubicin hydrochloride
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Medical University of South Carolina
Coronary Artery Disease
The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery
The purpose of the study is to find out if giving the study drug, Androgel (testosterone) as a testosterone replacement help bring the testosterone to an acceptable level and to find out if it will help improve heart condition in…
- Trial name
- NCT00413244
- Testing
- AndroGel 5 Grams
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Prostate Cancer
S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antiandrogen drugs, such as abiraterone acetate, may lessen the amount of androgens made by the body.
- Trial name
- NCT01309672
- Testing
- abiraterone acetate, Prednisone
- Where
- 205 sites in United States
- Volunteers
- 41 people
- Sponsor
- SWOG Cancer Research Network
Prostatic Neoplasms
Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
This is a Phase II study of docetaxel, bevacizumab, prednisone and thalidomide in patients with androgen independent metastatic prostate cancer who are previously untreated with chemotherapy.
- Trial name
- NCT00089609
- Testing
- Docetaxel, Thalidomide, Prednisone
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Respiratory Failure, Nutritional Depletion
IRAD2 : Patients With Respiratory Failure at Home
Title : Effects of home pulmonary rehabilitation in patients with chronic respiratory failure and nutritional depletion. This is a randomized controlled, open clinical trial with two groups.
- Trial name
- NCT00230984
- Testing
- education, Oral dietary supplements (563 kcal/d), RESPIFOR, exercises on an ergometric bicycle 3 to 5 times a week
- Where
- 8 sites in France, Switzerland
- Volunteers
- 200 people
- Sponsor
- University Hospital, Grenoble
Prostate Cancer
A Degarelix Trial in Patients With Prostate Cancer
A phase III extension trial comparing the efficacy and safety of degarelix 3 month depot with the established therapy Zoladex 3 month implant in patients with prostate cancer.
- Trial name
- NCT01242748
- Testing
- Degarelix, Goserelin acetate
- Where
- 63 sites in United States, Belgium and 11 more
- Volunteers
- 288 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
SABR Including Regional Lymph Node Irradiation for Patients With High Risk Prostate Cancer (SATURN)
Current treatment options for high risk localized prostate cancer include radical prostatectomy +/- postoperative radiotherapy, radical radiotherapy with androgen deprivation therapy.
- Trial name
- SATURN (NCT01953055)
- Testing
- Stereotactic ablative radiotherapy
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
Solid Tumor, Androgen Receptor Gene Overexpression
Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma
This study's purpose is to facilitate and expedite the clinical testing of SEVI-D in a population with advanced GBM that are androgen receptor (AR) positive.
- Trial name
- START (NCT03600467)
- Testing
- SEVI-D (Seviteronel in combination with dexamthasone)
- Where
- Australia
- Volunteers
- 4 people
- Sponsor
- St Vincent's Hospital, Sydney
Prostate Cancer
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004054
- Testing
- bicalutamide, estramustine phosphate sodium, etoposide
- Where
- 54 sites in United States, Canada
- Volunteers
- 397 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix
The aim of this phase IV interventional study is to evaluate variation in bone mineral density and lean and fat body composition in patients with prostate cancer without bone metastasis, treated with Degarelix.
- Trial name
- BLADE (NCT03202381)
- Testing
- Degarelix
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Prostate Cancer Recurrent
Firmagon (Degarelix) Intermittent Therapy
Men with localized prostate cancer requiring intermittent androgen deprivation therapy for biochemical recurrence following radical therapy will be asked to participate in a phase 4 safety and efficacy clinical trial comparing 10…
- Trial name
- FIT (NCT01512472)
- Testing
- degarelix
- Where
- 15 sites in Canada
- Volunteers
- 144 people
- Sponsor
- Canadian Urology Research Consortium
Prostate Adenocarcinoma, Prostate Carcinoma
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body.
- Conditions
- Prostate Adenocarcinoma, Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Cancer
- Trial name
- NCT00170157
- Testing
- Bicalutamide, Flutamide, Goserelin Acetate
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Mayo Clinic
Androgen Deprivation Therapy, Prostate Cancer
Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
The purpose of this research is to determine whether a 16-week culturally tailored, technology-based, aerobic and resistance exercise intervention improves cardiovascular risk factors in Black men diagnosed with prostate cancer…
- Conditions
- Androgen Deprivation Therapy, Prostate Cancer, Prostate Cancer Metastatic
- Trial name
- NCT05327465
- Testing
- Aerobic and resistance exercise, Usual Care
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate CA
Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate Cancer
The high incidence of prostate cancer is one of the important diseases that threaten the health of old men in our country. Although androgen deprivation therapy is an important treatment option for prostate cancer, although…
- Trial name
- NCT06834321
- Testing
- Homoharringtonine combined with androgen deprivation therapy, radical prostatectomy
- Where
- 2 sites in China
- Volunteers
- 96 people
- Sponsor
- baotai Liang
Prostatic Neoplasms
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
This is a non-comparative open-label multicenter Phase 2 clinical trial combining stereotactic body radiation therapy (SBRT) and pembrolizumab with or without intratumoral SD-101 in participants with newly diagnosed hormone-naive…
- Trial name
- NCT03007732
- Testing
- Pembrolizumab, SD-101, Leuprolide acetate
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- David Oh
Postoperative or Postradiation Adjuvant Androgen Deprivation Therapy in Locally Advanced Prostate Cancer (High and Very High Risk) Patients
Non-Interventional Study PREVENT
This is a multicentre, non-interventional, prospective study to be carried out in representative medical institutions in order to get the information on administration of postoperative and post-radiation adjuvant androgen…
- Trial name
- PREVENT (NCT02155998)
- Where
- 14 sites in Russia
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.